R3HCC1 and neutropenia: Our results showed that an SNP in R3HCC1 (c.919G > A, rs2272761) was useful as a biomarker of hematotoxicity, such as severe neutropenia, in patients who received irinotecan‐containing doublet chemotherapy (i.e., FOLFIRI) for mCRC.